<DOC>
	<DOCNO>NCT00609934</DOCNO>
	<brief_summary>The purpose study investigate use new anti-angiogenic drug call sorafenib , combination radiotherapy , renal cell cancer spread bone causing significant pain . The study find safe dose sorafenib combination study treatment , look side effect , test study treatment effective control pain experience type renal cell cancer . . There two part phase study The purpose first phase find high dose sorafenib give safely patient , combine radiotherapy . We also see kind effect study treatment cancer . Participants phase receive dose sorafenib show well-tolerated human . If side effect tolerable dose sorafenib combine radiotherapy , new patient ask join study receive dose sorafenib high last study participant . In second phase , new study participant receive dose sorafenib determine safe first phase . Side effect continue look effectiveness control pain symptom type cancer , also look .</brief_summary>
	<brief_title>Study Sorafenib Palliative Radiotherapy Kidney Cancer That Spreads Bone</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Eligibility Criteria 1 . Eligible patient must histologically cytologically confirm metastatic RCC judge incurable standard therapy . 2 . Patients must least one radiographicallyevident symptomatic ( &gt; 2/10 Brief Pain Inventory ) bone metastasis amenable palliative radiation . Multiple symptomatic bone metastasis may irradiate time . However , one symptomatic bone metastasis identify , one chosen index lesion reporting purpose . 3 . No planned change analgesic medication . 4 . No planned increase regular analgesic medication . 5 . No prior surgery index lesion , although previous surgery metastatic disease permissible &gt; 4 week prior study registration . 6 . Patients may two previous line systemic treatment metastatic RCC , include prior treatment sorafenib another similar multitargeted tyrosine kinase inhibitor , complete &gt; 4 week prior study registration . 7 . Patients may previous radiotherapy index lesion . Patients may previous radiotherapy metastasis complete &gt; 4 week prior study registration . Patients must recover acute side effect radiotherapy prior study registration . 8 . Age &gt; 18 year . 9 . Life expectancy great 3 month . 10 . ECOG performance status &lt; 2 ( Karnofsky &gt; 60 ) . 11 . Patients must normal organ marrow function define : . Absolute neutrophil count &gt; 1.5 x109 /L ii . Platelet count &gt; 75 x109 /L iii . Total bilirubin &lt; 1.5 x ULN iv . AST ( SGOT ) / ALT ( SGPT ) &lt; 2.5 Ã— institutional ULN &lt; 5 x institutional ULN liver metastasis v. Creatinine &lt; 1.7 x ULN vi . Creatinine clearance &gt; 50 mL/min/1.73 m2 vii . International Normalized Ratio ( INR ) &lt; 1.5 viii . Hemoglobin value Hb &gt; 80 g/L ix . Serum phosphate level &gt; 0.80 mmol/L x. Serum lipase , normal value ( range 5208 U/L ) xi . Serum amylase , normal value ( range 30110 U/L ) 12 . Ability understand willingness sign write informed consent document . 13 . The effect sorafenib develop human fetus recommend therapeutic dose unknown . Women childbearing potential must agree use adequate contraception prior study entry duration study participation . Effective method birth control would include barrier method ( e.g . condom , diaphragm ) combine spermicide , intrauterine device ( IUD ) . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Exclusion Criteria 1 . Serious medical condition might aggravate treatment , include limited : myocardial infarction within 6 month , congestive heart failure , unstable angina , active cardiomyopathy , unstable ventricular arrhythmia , uncontrolled hypertension , uncontrolled psychotic disorder , serious infection , active peptic ulcer disease , active liver disease , cerebrovascular disease previous stroke . 2 . Patients may receive investigational agent concurrently within 4 week study registration . Patients receive molecularlytargeted treatment RCC study , include inhibitor angiogenesis mTOR , eligible study 1 week washout period . 3 . Patients clinical radiological evidence spinal cord compression ineligible . 4 . Patients high risk pathologic fracture appropriate surgical intervention ineligible . 5 . Patients plan palliative surgical intervention index lesion adjacent bone ineligible . 6 . Pregnant lactate woman exclude study safety sorafenib establish circumstance . 7 . Patients immune deficiency increase risk lethal infection treat marrowsuppressive therapy . Therefore , HIVpositive patient receive combination antiretroviral therapy exclude study possible pharmacokinetic interaction sorafenib . 8 . Patients active malignancy nonmelanoma skin cancer exclude . 9 . Patients significant surgical procedure require general anaesthetic ( example , open laparotomy thoracotomy ) within past month 10 . Patients possess significant unhealed wound ulcer 11 . Patients bleed clot disorder 12 . Patient take great 325mg aspirin per day 13 . Patients diabetes mellitus ineligible PETCT component study , remain eligible receive sorafenib . 14 . Patients currently take rifampin , phenytoin , carbamazepine , Phenobarbital , dexamethasone St. John 's Wort .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>renal cell carcinoma</keyword>
	<keyword>kidney cancer</keyword>
	<keyword>bone metastasis</keyword>
	<keyword>RCC</keyword>
	<keyword>bone pain</keyword>
	<keyword>palliative radiotherapy</keyword>
	<keyword>sorafenib</keyword>
	<keyword>radiation</keyword>
	<keyword>renal cell</keyword>
</DOC>